SAN FRANCISCO, Oct. 24, 2007 (PRIME NEWSWIRE) -- Immunomedics, Inc. (NasdaqGM:IMMU - News), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced that its humanized anti-CD74 antibody, milatuzumab, showed promising therapeutic activity for B-cell lymphoma in animal models. This activity can be enhanced when combined with anti-CD20 antibodies. Rhona Stein, Ph.D., of the Garden State Cancer Center in Belleville, NJ, presented these preclinical results at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications in San Francisco, CA.
